Moderna came into this Q3 2026 report with a volatile reputation and a rich story stock label, yet the hard numbers just forced a reset. The share price jumped 5.3% to US$254.19 on the first full trading day after results, and this time the move matched something real. The messenger RNA specialist swung to a quarterly profit, posting US$162 million in net income on US$1.3b in revenue. That profit squeeze in reverse is what grabbed the market's attention. For a business still unprofitable over the last year, that shift is the headline.
Love Moderna's swing back into quarterly profit but uneasy that the business is still loss making over the last year? You can check out our list of stocks that pair consistent profitability with stronger balance sheets in the list of solid balance sheet and fundamentals stocks (24 results)
Q3 2026 Earnings Summary
-
Revenue (Q3 2026 vs. Q3 2025):US$1.313b vs. US$1.016b (up 29%)
-
Net Income/Loss (Q3 2026 vs. Q3 2025):Net income of US$162m vs. net loss of US$200m (moved back to profit)
-
Basic EPS (Q3 2026 vs. Q3 2025):US$0.40 per share vs. loss of US$0.51 per share (returned to positive earnings per share)
-
R&D Pipeline (Q3 2026 vs. Q2 2026):Phase I: 9 vs. 9 programs, Phase II: 16 vs. 16 programs, Phase III: 7 vs. 7 programs (pipeline count stable quarter on quarter)
Prefer clean visuals instead of dense tables and raw filings? See Moderna's full financial picture, with a clear snapshot of its valuation and key drivers, in the company report for Moderna.
Moderna's Multi‑Indication Ambition Meets First Real Test
The bullish story hangs on Moderna proving it can turn a broad mRNA toolkit into a real multi indication franchise, not just a COVID derivative.
"Some bullish analysts expect Moderna to turn its mRNA platform, respiratory vaccines and expanding oncology pipeline into a broad, multi-indication business that extends well beyond COVID vaccines."
Q3 gives the first concrete progress against that claim. Respiratory diversification moved from idea to execution with mFLUSIVA approved in the U.S. and Canada and combo respiratory shots cleared in Canada. Oncology stepped up from promise to pivotal data as intismeran delivered positive Phase 3 melanoma results with filings planned. Revenue still skews to COVID, yet the quarter finally shows non COVID assets contributing measurable commercial and clinical milestones.
Not everyone reads the same price the same way. → See the lower figure this Narrative lands on, and how it gets there .
Moderna's Q3 Profit Masks Thin Execution Proof
Bears argue Moderna's pipeline looks too light to justify the current build out. The sharp rally then raises the bar for every new data point.
"Bearish analysts expect Moderna's expanding oncology and respiratory vaccine pipeline to fall short of the revenue levels implied by its current valuation, especially after a very large post-data share price rally and delays such as the extended norovirus trial."
Q3 results partly push back. Respiratory approvals for mFLUSIVA and combo shots, plus melanoma Phase 3 success, are concrete wins. Yet norovirus still lacks a clear path after missing early criteria, oncology remains pre revenue, and the larger fixed cost base still leans on COVID weighted sales.
Hunt Quiet Fundamental Shifts Early
Moderna just showed how quickly sentiment can swing once a story meets hard numbers. The real opportunity is finding stocks that could be undervalued before the market corrects them.
-
Company 1 - 27% below our estimate - convert record program wins in regulated manufacturing into higher margin production while keeping cash discipline intact.
-
Company 2 - 31% below our estimate - shift a niche lending platform onto a bank funded, automated model using new deposits, tax assets and faster product cycles.
-
Company 3 - 41% below our estimate - use AI driven tools and stricter carrier vetting to raise heavy haul productivity while containing fraud, insurance and claims costs.
That is three of the list. See the full list of 40 companies trading below our fair value estimates →
This article is general in nature and was produced with the assistance of AI automation, based on data and analysis from Simply Wall St. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include MRNA .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
